Moelis & Company
MC
$56.39
-2.08%
Moelis & Company is an independent investment bank that provides strategic and financial advisory services — including mergers and acquisitions, recapitalizations, restructurings, and capital markets transactions — to corporations, financial sponsors, governments, and sovereign wealth funds across all major industry sectors. Unlike bulge-bracket universal banks, Moelis operates a pure-play, conflict-free advisory model with no lending or trading book, which positions it as a trusted counselor on complex, high-stakes transactions and distinguishes it as a boutique advisory leader alongside peers like Evercore, Centerview, and PJT Partners. The current investor narrative centers on the firm's sharp earnings recovery, with Q4 2025 revenue of $487.9 million up 11.2% year-over-year and net income of $87.9 million, as a broadening M&A recovery and restructuring activity drive results. However, the stock has been a notable laggard, down roughly 15% over the past year and underperforming the S&P 500 by more than 31 percentage points, leaving investors debating whether the earnings rebound is already priced in or whether the underperformance represents a compelling entry point ahead of a sustained dealmaking cycle.…
MC
Moelis & Company
$56.39
Related headlines
Investment Opinion: Should I buy MC Today?
We rate MC as a Hold with a bias toward accumulation on weakness. The core thesis is that the company is experiencing a cyclical earnings recovery, with Q4 2025 revenue up 11.2% YoY and forward EPS estimated at $4.10, yet the stock trades at a forward PE of only 16.3x and offers 12.4% upside to the average analyst target of $72.00. However, the persistent underperformance and high short interest warrant caution until a sustained rebound in dealmaking is confirmed.
The supporting evidence is compelling: revenue growth of 11.2% YoY, a net margin of 15.4%, ROE of 41.0%, and a fortress balance sheet with a current ratio of 21.5x and debt-to-equity of 0.47. The dividend yield of 4.0% provides income, and the forward PE of 16.3x is below the trailing PE of 22.1x, suggesting earnings are expected to grow. The PEG ratio of 0.34 is attractive, implying undervaluation relative to growth. However, the price-to-book of 9.07x is a concern, and the stock's 1-year relative strength of -31.6% versus the S&P 500 highlights the risk of catching a falling knife.
The biggest risks are a stall in M&A activity, earnings volatility, and high beta. The rating would upgrade to Buy if the stock pulls back to the $55-58 range (closer to the 52-week low) or if forward EPS estimates are revised upward, confirming the recovery. It would downgrade to Sell if revenue growth turns negative or if the forward PE exceeds 20x without corresponding earnings growth. Relative to its history and peers, MC appears undervalued on a forward earnings basis but fairly valued on book value, making it a hold for value-oriented investors with a tolerance for volatility.
Sign up to view all
MC 12-Month Price Forecast
Moelis is a high-quality boutique advisory firm with a strong balance sheet and a cyclical earnings recovery underway. The forward PE of 16.3x and PEG of 0.34 suggest the stock is undervalued relative to its growth potential, and the 12.4% upside to the average analyst target is attractive. However, the stock's severe underperformance, high beta, and elevated price-to-book ratio warrant a neutral stance until there is clearer evidence of a sustained M&A rebound. We would upgrade to bullish if Q1 2026 earnings show accelerating revenue growth and margin expansion, or if the stock pulls back to the $55-58 range, improving the risk/reward. Conversely, a downgrade to bearish would occur if forward EPS estimates are revised downward or if deal activity shows signs of stalling.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Moelis & Company's 12-month outlook, with a consensus price target around $67.50 and implied upside of +19.7% versus the current price.
Average Target
$67.50
0 analysts
Implied Upside
+19.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$58 - $80
Analyst target range
Bulls vs Bears: MC Investment Factors
The bull case rests on a clear earnings recovery, a discounted forward PE of 16.3x, and a fortress balance sheet with a 41% ROE. However, the bear case is equally compelling: the stock has massively underperformed the market, trades at a premium price-to-book, and exhibits high earnings volatility and beta. The most critical tension is whether the M&A cycle will sustain its recovery; if it does, the forward earnings estimate of $4.10 could drive the stock toward the $72 average target. Conversely, if deal activity stalls, the high beta and premium valuation could lead to a retest of the 52-week low of $51.06. Currently, the bear evidence appears slightly stronger due to the persistent relative weakness and high short interest, but the valuation gap provides a potential catalyst for a reversal.
Bullish
- Earnings recovery accelerating: Q4 2025 revenue of $487.9M rose 11.2% YoY, while net income jumped to $87.9M from $89.4M in Q4 2024 despite the revenue gain, and diluted EPS of $1.10 was solid. More importantly, Q4 EBITDA margin expanded to 29.0% from 30.6% a year ago, but the absolute EBITDA of $141.3M was up 5.2% YoY, signaling operating leverage as deal activity broadens.
- Deeply discounted forward PE: The stock trades at a forward PE of just 16.3x based on estimated EPS of $4.10, versus a trailing PE of 22.1x. This implies the market is pricing in a sharp earnings rebound that has not yet been reflected in the share price, creating a potential valuation gap if the M&A cycle continues to recover.
- Analyst target implies 12.4% upside: The average analyst target price is $72.00, representing 12.4% upside from the current price of $64.03. The high target of $86.00 implies 34.3% upside, suggesting that even the most conservative analyst sees the stock as undervalued relative to its earnings power.
- Fortress balance sheet: With a current ratio of 21.5x and debt-to-equity of only 0.47, Moelis has ample liquidity and minimal leverage. This provides flexibility to invest in talent, return capital via dividends (4.0% yield), and weather cyclical downturns without financial distress.
Bearish
- Severe relative underperformance: MC is down 15.4% over the past year while the S&P 500 gained 16.2%, a massive 31.6 percentage point underperformance. This persistent weakness suggests deep-seated concerns about the sustainability of the earnings recovery or structural challenges in the advisory business.
- High beta amplifies downside: With a beta of 1.84, MC is nearly twice as volatile as the broader market. In a risk-off environment or if M&A activity stalls, the stock could experience amplified declines, as evidenced by a max drawdown of -33.9%.
- Earnings volatility and cyclicality: Quarterly EPS has been highly volatile, ranging from $0.18 in Q2 2024 to $1.24 in Q4 2024, and net income margin swung from 4.9% to 20.4% over the same period. This earnings instability makes forecasting difficult and can lead to sharp stock price reactions.
- Premium valuation on book value: The price-to-book ratio of 9.07x is exceptionally high for a financial services firm, indicating that investors are paying a hefty premium for intangible assets like human capital and brand. If earnings disappoint, the stock could de-rate sharply.
MC Technical Analysis
Beta
1.90
1.90x market volatility
Max Drawdown
-33.9%
Largest decline past year
52-Week Range
$51-$78
Price range past year
Annual Return
-14.3%
Cumulative gain past year
| Period | MC Return | S&P 500 |
|---|---|---|
| 1m | -11.9% | +1.8% |
| 3m | -19.5% | +3.1% |
| 6m | -15.9% | +10.9% |
| 1y | -14.3% | +17.3% |
| ytd | -20.8% | +14.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MC Fundamental Analysis
Quarterly Revenue
$487935000.0B
2025-12
Revenue YoY Growth
+11.2%
YoY Comparison
Gross Margin
99.3%
Latest Quarter
Free Cash Flow
$539967000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MC Overvalued?
PE
22.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 8x~60x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are moderate but notable. The company carries a debt-to-equity ratio of 0.47, which is manageable, but its current ratio of 21.5x reflects a cash-rich balance sheet that could be deployed inefficiently. More concerning is the earnings volatility: quarterly EPS has ranged from $0.18 to $1.24 over the past eight quarters, and net margin has fluctuated between 4.9% and 20.4%. This instability stems from the lumpy nature of advisory fees, which are dependent on the timing and size of M&A transactions. Additionally, the payout ratio of 89.6% is high, leaving little room for error if earnings decline, and the dividend yield of 4.0% may not be sustainable if profits falter.
Market and competitive risks are significant. The stock's beta of 1.84 means it is highly sensitive to market swings, and a broader market correction could disproportionately impact MC. The price-to-book ratio of 9.07x is elevated compared to traditional financial firms, making the stock vulnerable to valuation compression if growth expectations are not met. Competition from both bulge-bracket banks and other boutiques like Evercore and PJT Partners is intense, and any loss of key talent could harm the franchise. Furthermore, the lack of recent news coverage suggests limited near-term catalysts, which could lead to continued relative underperformance.
The worst-case scenario would involve a sharp slowdown in global M&A activity due to rising interest rates or geopolitical shocks, causing advisory revenues to decline and earnings to miss estimates. In this scenario, the stock could retest its 52-week low of $51.06, representing a 20.3% decline from the current price of $64.03. If the bear case target of $60.00 is breached, the next support level would be the 52-week low, implying a total downside of approximately 20%. A more severe downturn, similar to the max drawdown of -33.9%, would take the stock to around $42.30, a 34% loss. Investors should be prepared for significant volatility given the high beta and cyclical nature of the business.
FAQ
The key risks for MC are ranked as follows: 1) Cyclical earnings risk – advisory revenues are highly dependent on M&A activity, and a recession could cause a sharp decline in deal volume, as seen in the 4.9% net margin in Q2 2024. 2) Valuation risk – the price-to-book of 9.07x leaves little room for error, and any earnings miss could trigger a significant de-rating. 3) Market risk – with a beta of 1.84, the stock is nearly twice as volatile as the market, and a broad selloff could amplify losses. 4) Competitive risk – intense competition from bulge-bracket banks and other boutiques could pressure fees and market share. Additionally, the high short ratio of 6.22 indicates that many investors are betting against the stock, which could exacerbate downside moves.
Our 12-month forecast for MC includes three scenarios. The base case (55% probability) targets $68-76, assuming moderate M&A recovery and EPS of $4.10, aligning with the analyst average target of $72.00. The bull case (25% probability) targets $80-86, driven by a robust dealmaking environment and EPS of $4.56, with the stock re-rating to 18-19x forward earnings. The bear case (20% probability) targets $51-60, reflecting a recession or deal stall that pushes the stock back to its 52-week low of $51.06. The most likely scenario is the base case, with the key assumption being that global M&A volume grows 10-15% in 2026. Investors should monitor quarterly earnings for confirmation of this trend.
MC appears undervalued on forward earnings but overvalued on book value. The forward PE of 16.3x is below the trailing PE of 22.1x, suggesting the market expects earnings growth. The PEG ratio of 0.34 is also attractive, indicating the stock is cheap relative to its growth rate. However, the price-to-book ratio of 9.07x is very high for a financial services firm, reflecting the value of intangible assets like human capital. Compared to peers like Evercore and PJT Partners, MC's forward PE is in line, but its price-to-book is at a premium. The market is pricing in a successful execution of the earnings recovery; if that fails, the stock could de-rate. Overall, the valuation is fair to slightly undervalued based on forward earnings, but not a deep value play.
MC presents a mixed risk/reward profile. On the positive side, the stock trades at a forward PE of 16.3x, well below its trailing PE of 22.1x, and offers 12.4% upside to the average analyst target of $72.00. The company has a fortress balance sheet with a current ratio of 21.5x and a 4.0% dividend yield. However, the stock has underperformed the S&P 500 by 31.6 percentage points over the past year, and its high beta of 1.84 means it could decline sharply in a market downturn. The biggest downside risk is a stall in M&A activity, which could push the stock back to its 52-week low of $51.06, a 20% decline. For investors with a long-term horizon and tolerance for volatility, MC could be a good buy on weakness, but it is not a low-risk investment.
MC is more suitable for long-term investment than short-term trading. The company operates in a cyclical industry with lumpy earnings, making short-term price movements unpredictable. Its high beta of 1.84 and earnings volatility (EPS ranging from $0.18 to $1.24 in recent quarters) make it risky for short-term traders. However, for long-term investors, the stock offers a 4.0% dividend yield, a strong balance sheet, and exposure to a potential multi-year M&A recovery. A minimum holding period of 2-3 years is recommended to ride out the cycles and benefit from the earnings recovery. Short-term traders might find opportunities around earnings announcements, but they should be aware of the high risk. Overall, MC is best suited for patient investors with a long-term horizon.